Balentine LLC’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $256K | Buy |
+515
| New | +$228K | 0.01% | 171 |
|
|
2024
Q2 | – | Sell |
-10,103
| Closed | -$4.22M | – | 571 |
|
|
2024
Q1 | $4.22M | Sell |
10,103
-81
| -0.8% | -$34.2K | 0.13% | 56 |
|
|
2023
Q4 | $4.14M | Buy |
10,184
+463
| +5% | +$171K | 0.13% | 60 |
|
|
2023
Q3 | $3.38M | Buy |
9,721
+11
| +0.1% | +$3.85K | 0.11% | 62 |
|
|
2023
Q2 | $3.42M | Buy |
9,710
+689
| +8% | +$232K | 0.11% | 63 |
|
|
2023
Q1 | $2.84M | Sell |
9,021
-149
| -2% | -$44.7K | 0.1% | 73 |
|
|
2022
Q4 | $2.65M | Buy |
9,170
+464
| +5% | +$141K | 0.09% | 79 |
|
|
2022
Q3 | $2.52M | Sell |
8,706
-2,154
| -20% | -$620K | 0.1% | 64 |
|
|
2022
Q2 | $3.06M | Buy |
10,860
+8,357
| +334% | +$2.24M | 0.11% | 71 |
|
|
2022
Q1 | $653K | Buy |
+2,503
| New | +$594K | 0.02% | 247 |
|
|
2020
Q4 | – | Sell |
-952
| Closed | -$259K | – | 189 |
|
|
2020
Q3 | $259K | Sell |
952
-19
| -2% | -$5.24K | 0.01% | 105 |
|
|
2020
Q2 | $282K | Buy |
971
+49
| +5% | +$13.3K | 0.02% | 71 |
|
|
2020
Q1 | $219K | Buy |
922
+341
| +59% | +$78.2K | 0.01% | 60 |
|
|
2019
Q4 | $127K | Buy |
581
+285
| +96% | +$57.7K | 0.01% | 101 |
|
|
2019
Q3 | $50K | Hold |
296
| – | – | ﹤0.01% | 134 |
|
|
2019
Q2 | $54K | Buy |
296
+35
| +13% | +$6.12K | ﹤0.01% | 103 |
|
|
2019
Q1 | $48K | Hold |
261
| – | – | ﹤0.01% | 124 |
|
|
2018
Q4 | $43K | Hold |
261
| – | – | ﹤0.01% | 122 |
|
|
2018
Q3 | $50K | Buy |
+261
| New | +$46.5K | ﹤0.01% | 70 |
|
|
2018
Q1 | – | Sell |
-649
| Closed | -$97K | – | 508 |
|
|
2017
Q4 | $97K | Hold |
649
| – | – | 0.01% | 196 |
|
|
2017
Q3 | $99K | Sell |
649
-197
| -23% | -$29.7K | 0.01% | 189 |
|
|
2017
Q2 | $109K | Sell |
846
-24
| -3% | -$2.89K | 0.01% | 158 |
|
|
2017
Q1 | $95K | Hold |
870
| – | – | 0.01% | 171 |
|
|
2016
Q4 | $64K | Buy |
870
+235
| +37% | +$19.1K | 0.01% | 188 |
|
|
2016
Q3 | $55K | Buy |
635
+506
| +392% | +$47.8K | 0.01% | 162 |
|
|
2016
Q2 | $11K | Buy |
+129
| New | +$11.1K | ﹤0.01% | 334 |
|
|
2015
Q4 | – | Sell |
-503
| Closed | -$52K | – | 476 |
|
|
2015
Q3 | $52K | Sell |
503
-73
| -13% | -$9.38K | 0.01% | 166 |
|
|
2015
Q2 | $71K | Buy |
576
+73
| +15% | +$9.2K | 0.01% | 123 |
|
|
2015
Q1 | $59K | Buy |
+503
| New | +$60.3K | 0.01% | 125 |
|
Other funds holding VRTX
Balentine LLC's VRTX Position: Q2 2026 in Review
Balentine LLC opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 515 shares worth $256K. The stake represents 0.01% of the portfolio and ranks #171 among its holdings. This is a return to the name: Balentine LLC previously reported a position in VRTX as recently as Q1 2024.
Balentine LLC first reported a position in VRTX in Q1 2015 and has held it in 29 quarters since. The position peaked at $4.22M in Q1 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Balentine LLC held 515 shares of Vertex Pharmaceuticals worth $256K as of Q2 2026.
- Vertex Pharmaceuticals was a new Balentine LLC position in Q2 2026.
- Vertex Pharmaceuticals made up 0.01% of Balentine LLC's portfolio in Q2 2026, its #171 holding.
- Balentine LLC first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 29 quarters since.
- Balentine LLC's Vertex Pharmaceuticals position peaked at $4.22M in Q1 2024.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Balentine LLC's 13F filing for Q2 2026, filed 6 Aug 2026.